1. Academic Validation
  2. Enzyme-Triggered Morphological Transition of Peptide Nanostructures for Tumor-Targeted Drug Delivery and Enhanced Cancer Therapy

Enzyme-Triggered Morphological Transition of Peptide Nanostructures for Tumor-Targeted Drug Delivery and Enhanced Cancer Therapy

  • ACS Appl Mater Interfaces. 2019 May 8;11(18):16357-16366. doi: 10.1021/acsami.9b03519.
Meiwen Cao 1 Sha Lu 1 Ningning Wang 1 Hai Xu 1 Henry Cox 2 Ruiheng Li 2 Thomas Waigh 2 Yuchun Han 3 Yilin Wang 3 Jian R Lu 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, College of Chemical Engineering , China University of Petroleum (East China) , 66 Changjiang West Road , Qingdao 266580 , China.
  • 2 Biological Physics Laboratory, School of Physics and Astronomy , University of Manchester , Schuster Building, Oxford Road , Manchester M13 9PL , U. K.
  • 3 Beijing National Laboratory for Molecular Sciences (BNLMS), Key Laboratory of Colloid and Interface Science , Institute of Chemistry, Chinese Academy of Sciences , Beijing 100190 , China.
Abstract

The use of smart drug carriers to realize cancer-targeted drug delivery is a promising method to improve the efficiency of chemotherapy and reduce its side effects. A surfactant-like peptide, Nap-FFGPLGLARKRK, was elaborately designed for cancer-targeted drug delivery based on an enzyme-triggered morphological transition of the self-assembled nanostructures. The peptide has three functional motifs: the aromatic motif of Nap-FF- to promote peptide self-assembly, the enzyme-cleavable segment of -GPLGLA- to introduce Enzyme sensitivity, and the positively charged -RKRK- segment to balance the molecular amphiphilicity as well as to facilitate interaction with cell membranes. The peptide self-assembles into long fibrils with hydrophobic inner cores, which can encapsulate a high amount of Anticancer drug doxorubicin (DOX). By having Enzyme responsibility, these fibrils can be degraded into thinner ones by the cancer-overexpressed matrix metalloproteinase-7 (MMP7) at tumor sites and precipitate out to give sustained release of DOX, resulting in cancer-targeted drug delivery and selective Cancer killing. In vivo antitumor experiments with mice confirm the high efficiency of such enzyme-responsive peptidic drug carriers in successfully suppressing the tumor growth and metastasis while greatly reducing the side effects. The study demonstrates the feasibility of using enzyme-sensitive peptide nanostructures for efficient and targeted drug delivery, which have great potential in biomedical Cancer treatment.

Keywords

cancer therapy; drug carriers; enzyme-sensitive; peptide self-assembly; targeted delivery.

Figures
Products